Granted Patent
B2
US 12,351,631 · App. 18/455,181 · Granted Jul 8, 2025
Anti-CD200R1 antibodies and methods of use thereof
Inventors:
Yu Chen (Foster City, CA); Jilean Beth Fenaux (San Mateo, CA); Germaine Fuh-Kelly (Pacifica, CA); Yao-Ming Huang (San Mateo, CA); Wei-Jen Chung (El Granada, CA); Erik Karrer (Los Altos, CA); Cecilia Lay (Brisbane, CA); Steven J. Pitts (San Francisco, CA); Louise Scharf (Redwood City, CA)
Assignee:
23andMe, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD200R1 receptor protein (hu-CD200R1) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD200R1. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD200 binding to CD200R1.
Claims (18)
1. A method of treating a CD200R1 mediated disease in a subject, wherein the disease is selected from clear cell renal carcinoma and neuroendocrine tumors, the method comprising administering to the subject a therapeutically effective amount of an anti-CD200R1 antibody, wherein the antibody comprises (i) a first light chain hypervariable region (HVR-L1), a second light chain hypervariable region (HVR-L2), and a third light chain hypervariable region (HVR-L3); and (ii) a first heavy chain hypervariable region (HVR-H1), a second heavy chain hypervariable region (HVR-H2), and a third heavy chain hypervariable region (HVR-H3), comprising:
(a) HVR-L1 of SEQ ID NO: 11, HVR-L2 of SEQ ID NO: 12, and HVR-L3 of SEQ ID NO: 13; and HVR-H1 of SEQ ID NO: 15, HVR-H2 of SEQ ID NO: 16, and HVR-H3 of SEQ ID NO: 17;
(b) HVR-L1 of SEQ ID NO: 19, HVR-L2 of SEQ ID NO: 20, and HVR-L3 of SEQ ID NO: 21; and HVR-H1 of SEQ ID NO: 23, HVR-H2 of SEQ ID NO: 24, and HVR-H3 of SEQ ID NO: 25;
(c) HVR-L1 of SEQ ID NO: 27, HVR-L2 of SEQ ID NO: 28, and HVR-L3 of SEQ ID NO: 29; and HVR-H1 of SEQ ID NO: 31, HVR-H2 of SEQ ID NO: 32, and HVR-H3 of SEQ ID NO: 33;
(d) HVR-L1 of SEQ ID NO: 35, HVR-L2 of SEQ ID NO: 36, and HVR-L3 of SEQ ID NO: 37; and HVR-H1 of SEQ ID NO: 39, HVR-H2 of SEQ ID NO: 40, and HVR-H3 of SEQ ID NO: 41;
(e) HVR-L1 of SEQ ID NO: 43, HVR-L2 of SEQ ID NO: 44, and HVR-L3 of SEQ ID NO: 45; and HVR-H1 of SEQ ID NO: 47, HVR-H2 of SEQ ID NO: 48, and HVR-H3 of SEQ ID NO: 49;
(f) HVR-L1 of SEQ ID NO: 51, HVR-L2 of SEQ ID NO: 52, and HVR-L3 of SEQ ID NO: 53; and HVR-H1 of SEQ ID NO: 55, HVR-H2 of SEQ ID NO: 56, and HVR-H3 of SEQ ID NO: 57;
(g) HVR-L1 of SEQ ID NO: 59, HVR-L2 of SEQ ID NO: 60, and HVR-L3 of SEQ ID NO: 61; and HVR-H1 of SEQ ID NO: 63, HVR-H2 of SEQ ID NO: 64, and HVR-H3 of SEQ ID NO: 65;
(h) HVR-L1 of SEQ ID NO: 77, HVR-L2 of SEQ ID NO: 78, and HVR-L3 of SEQ ID NO: 79; and HVR-H1 of SEQ ID NO: 81, HVR-H2 of SEQ ID NO: 82, and HVR-H3 of SEQ ID NO: 83;
(i) HVR-L1 of SEQ ID NO: 11, HVR-L2 of SEQ ID NO: 12, and HVR-L3 of SEQ ID NO: 13; and HVR-H1 of SEQ ID NO: 85, HVR-H2 of SEQ ID NO: 86, and HVR-H3 of SEQ ID NO: 87;
(j) HVR-L1 of SEQ ID NO: 11, HVR-L2 of SEQ ID NO: 12, and HVR-L3 of SEQ ID NO: 13; and HVR-H1 of SEQ ID NO: 81, HVR-H2 of SEQ ID NO: 82, and HVR-H3 of SEQ ID NO: 83; or
(k) HVR-L1 of SEQ ID NO: 77, HVR-L2 of SEQ ID NO: 78, and HVR-L3 of SEQ ID NO: 79; and HVR-H1 of SEQ ID NO: 85, HVR-H2 of SEQ ID NO: 86, and HVR-H3 of SEQ ID NO: 87.
2. The method of claim 1 , wherein the therapeutically effective amount is at least about 1 mg/kg.
3. The method of claim 1 , wherein the therapeutically effective amount is at least about 0.3 mg.
4. The method of claim 1 , wherein the therapeutically effective amount is at least about 10 mg/kg.
5. The method of claim 1 , wherein there are no significant off-target effects of the antibody at the therapeutically effective amount.
6. The method of claim 1 , wherein there are no significant off-target effects of the antibody at a dose of not more than 10 mg/kg.
7. The method of any one of claim 1 , wherein there are no significant off-target effects of the antibody at a dose of not more than 20 mg/kg.
Assignments (3)
CHANGE OF NAME
Recorded Nov 4, 2025
From: 23ANDME PGS LLC
To: 23ANDME GENOMICS LLC
Reel/Frame 073465/0812 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 15, 2025
From: 23ANDME, INC.
To: 23ANDME PGS LLC
Reel/Frame 073079/0250 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 29, 2023
From: CHEN, YU; CHUNG, WEI-JEN; FENAUX, JILEAN BETH; HUANG, YAO-MING; KARRER, ERIK EDWARD; LAY, CECILIA; PITTS, STEVEN J.; SCHARF, LOUISE; FUH-KELLY, GERMAINE
To: 23ANDME, INC.
Reel/Frame 064735/0299 →
Continuity (3)
Provisional Application
63032508
· May 29, 2020
References Cited (95)
EP 2341143A
· 2011
[cited by applicant]
JP 2007518827
· 2007
[cited by applicant]
JP 2010512791A
· 2010
[cited by applicant]
WO 2007042573
· 2007
[cited by applicant]
WO 2009121162A
· 2009
[cited by applicant]
WO 2015057906A
· 2015
[cited by applicant]
WO 2019067499
· 2019
[cited by applicant]
WO 2020055943
· 2020
[cited by applicant]
Fenaux J et al (2023) 23ME-00610, a genetically informed, first-in-class antibody targetingCD200R1 to enhance antitumor T cell function, OncoImmunology, 12:1, 2217737. (Year: 2023).
[cited by examiner]
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study. First posted Sep. 14, 2024. Accessed Sep. 19, 2024: https://investors.23andme.com/no…
[cited by examiner]
Li Y et al. Aberrant CD200/CD200R1 expression and function in systemic lupus erythematosus contributes to abnormal T-cell responsiveness and dendritic cell activity. Arthritis Res Ther. May 23, 2012;14(3):R123. (Year: 2…
[cited by examiner]
Xin Xie et al., “Monocytes, microglia, and CD200-CD200R1 signaling are essential in the transmission of inflammation from the periphery to the central nervous system”, J Neurochem., 2017, vol. 141, pp. 222 to 235 (Year:…
[cited by examiner]
Almagro JC, Fransson J. Humanization of antibodies. Front Biosci. Jan. 1, 2008;13:1619-33. (Year: 2008).
[cited by applicant]
Chen et al. Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations. EMBO J. Jun. 15, 1995; 14(12): 2784-94. (Year: 1995).
[cited by applicant]
Kussie et al. A single engineered amino acid substitution changes antibody fine specificity.J Immunol. Jan. 1, 1994;152(1):146-52. (Year: 1994).
[cited by applicant]
Koenig et al. Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding.PNAS Jan. 24, 2017 114(4)E486-E495;f irstpublished Jan. 5, 2017. (Y…
[cited by applicant]
Edwards et al. The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. Journal of Molecular Biology 334:103-118; (2003). (Year: 2003).
[cited by applicant]
Mathieu Dondelinger et al, “Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition”, Frontiers in Immunology, (Oct. 16, 2018), vol. 9, doi:10.3389/fimmu.2018…
[cited by applicant]
Inbal Sela-Culang et al, “The Structural Basis of Antibody-Antigen Recognition”, Frontiers in Immunology, (Oct. 8, 2013), vol. 4, doi:10.3389/fimmu.2013.00302, XP055557261 DOI: http://dx.doi.org/10.3389/fimmu.2013.00302.
[cited by applicant]
Moreaux et al., “CD200 is a new prognostic factor in multiple myeloma,” Blood, vol. 108, No. 13: 4194-4197 (Dec. 15, 2006).
[cited by applicant]
Moreaux et al., “CD200: A putative therapeutic target in cancer,” Biochemical and Biophysical Research Communications 366 (2008) 117-122.
[cited by applicant]
Mukhopadhyay et al., “Immune Inhibitory Ligand CD200 Induction by TLRs and NLRs Limits Macrophage Activation to Protect the Host from Meningococcal Septicemia,” Cell Host & Microbe 8, 236-247, Sep. 16, 2010.
[cited by applicant]
Rexin et al., “The Immune Checkpoint Molecule CD200 is Associated with Tumor Grading and Metastasis in Bladder Cancer,” Anticancer Research 38: 2749-2754 (2018); doi:10.21873/anticanres.12517.
[cited by applicant]
Rijkers et al., “The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes,” Molecular Immunology 45 (2008) 1126-1135.
[cited by applicant]
Saber et al., “An FDA oncology analysis of immune activating products and first-in-human dose selection,” Regulatory Toxicology and Pharmacology 81 (2016) 448-456. dx.doi.org/10.1016/j.yrtph.2016.10.002.
[cited by applicant]
Salek et al., “CD200R1 regulates eosinophilia during pulmonary fungal infection in mice,” Eur. J. Immunol. 2019. 49: 1380-1390. DOI: 10.1002/eji.201847861.
[cited by applicant]
Schoenfeld et al., “Acquired Resistance to Immune Checkpoint Inhibitors,” Cancer Cell 37: 443-455 (Apr. 13, 2020). DOI: 10.1016/j.ccell.2020.03.017.
[cited by applicant]
Shields et al., “High Resolution Mapping of the Binding Site on Human IgG1 for FcgRI, FcgRII, FcgRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcgR,” The Journal of Biological Chemistry, vol. 2…
[cited by applicant]
Shiratori et al., “Down-Regulation of Basophil Function by Human CD200 and Human Herpesvirus-8 CD200,” J Immunol 2005; 175:4441-4449; doi: 10.4049/jimmunol.175.7.4441.
[cited by applicant]
Siva et al., “Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200,” Cancer Immunol Immunother (2008) 57:987-996. DOI 10.1007/s00262-007-0429-6.
[cited by applicant]
Snelgrove et al., “A critical function for CD200 in lung immune homeostasis and the severity of influenza infection,” Nature Immunology, vol. 9, No. 9, pp. 1074-1083. (Sep. 2008).
[cited by applicant]
Sun et al., “CD200R, a co-inhibitory receptor on immune cells, predicts the prognosis of human hepatocellular carcinoma,” Immunology Letters 178 (2016) 105-113. DOI: 10.1016/j.imlet.2016.08.009.
[cited by applicant]
Thommen et al., “A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in nonsmall-cell lung cancer treated with PD-1 blockade,” Nature Medicine, vol. 24: 994-1004 (Jul. 2018).
[cited by applicant]
Tonks et al., “CD200 as a prognostic factor in acute myeloid leukaemia,” Leukemia (2007) 21, 566-568. doi:10.1038/sj.leu.2404559; published online Jan. 25, 2007.
[cited by applicant]
VanMeer et al., “Immunogenicity of mAbs in non-human primates during nonclinical safety assessment,” mAbs 5:5, 810-816; Sep./Oct. 2013.
[cited by applicant]
Wang et al., “Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy,” Nature Medicine, vol. 25: 656-666. (Apr. 2019).
[cited by applicant]
Wright et al., “Lymphoid/Neuronal Cell Surface OX2 Glycoprotein Recognizes a Novel Receptor on Macrophages Implicated in the Control of Their Function,” Immunity, vol. 13, 233-242 (Aug. 2000).
[cited by applicant]
Wright et al., “The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans,” Immunology 102:173-179 (2001).
[cited by applicant]
Wright et al., “Characterization of the CD200 Receptor Family in Mice and Humans and Their Interactions with CD200,” J Immunol 171:3034-3046 (2003).
[cited by applicant]
Zhang et al., “Molecular Mechanisms of CD200 Inhibition of Mast Cell Activation,” J Immunol 173:6786-6793 (2004).
[cited by applicant]
Zheng et al., “Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing,” Cell 169, 1342-1356. Jun. 15, 2017.
[cited by applicant]
Zou et al., “Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon,” Oncogene (2002) 21, 4855-4862.
[cited by applicant]
PCT International Search Report and Written Opinion of the International Search Authority for PCT application No. PCT/US2021/034852. Nov. 9, 2021.
[cited by applicant]
Akkaya et al., “Dissection of Agonistic and Blocking Effects of CD200 Receptor Antibodies,” PLOS ONE, vol. 8, No. 5, May 14, 2013, p. e63325, XP055647634, DOI: 10.1371/journal.pone.0063325.
[cited by applicant]
Gorczynski, “CD200:CD200R-mediated regulation of immunity.” ISRN Immunology, vol. 2012; Article ID 682168, 18 pages doi:10.5402/2012/682168.
[cited by applicant]
Rygiel T P, Meyaard L. “CD200R signaling in tumor tolerance and inflammation: a tricky balance.” Curr Opin Immunol. 2012; 24(2):233-8.
[cited by applicant]
McWhirter et al. “Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation.” Proc Natl Acad Sci USA. 2006; 103(4):1041-6.
[cited by applicant]
Mahadevan et al., “Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200,” J. Immunotherapy Cancer 7, 227 (2019).
[cited by applicant]
Achyut et al., “Canonical NFκB signaling in myeloid cells is required for the glioblastoma growth,” Scientific Reports 7:13754; published online: Oct. 23, 2017; DOI:10.1038/s41598-017-14079-4.
[cited by applicant]
Akkaya et al., “Heterogeneity in the CD200R paired receptor family,” Immunogenetics (2010) 62:15-22, DOI 10.1007/s00251-009-0415-6.
[cited by applicant]
Alapat et al., “Diagnostic Usefulness and Prognostic Impact of CD200 Expression in Lymphoid Malignancies and Plasma Cell Myeloma,” Am J Clin Pathol. Jan. 2012 ; 137(1): 93-100. doi:10.1309/AJCP59UORCYZEVQO.
[cited by applicant]
Ambarus et al., “Systematic validation of specific phenotypic markers for in vitro polarized human macrophages,” Journal of Immunological Methods 375 (2012) 196-206; doi:10.1016/j.jim.2011.10.013.
[cited by applicant]
Bensch et al., “89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer,” Nature Medicine, vol. 24: 1852-1858. (Dec. 2018); https://doi.org/10.1038/s41591-018-0255-8.
[cited by applicant]
Betts et al., “Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgen…
[cited by applicant]
Caserta et al., “Chronic Infection Drives Expression of the Inhibitory Receptor CD200R, and Its Ligand CD200, by Mouse and Human CD4 T Cells,” PloS ONE, vol. 7, Issue 4, e35466 (Apr. 2012).
[cited by applicant]
Cassetta et al., “Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets.” Cancer Cell 35 588-602.e510. (2019).
[cited by applicant]
Cerignoli et al., “In vitro immunotherapy potency assays using real-time cell analysis,” PLOS ONE | https://doi.org/10.1371/journal.pone.0193498, Mar. 2, 2018.
[cited by applicant]
Chen et al., “Role of a distal enhancer in the transcriptional responsiveness of the human CD200 gene to interferon-gamma and tumor necrosis factor-alpha,” Molecular Immunology 46 (2009) 1951-1963; doi:10.1016/j.molimm.…
[cited by applicant]
Choueiry et al., “CD200 promotes immunosuppression in the pancreatic tumor microenvironment,” J. Immunother. Cancer 2020;8:e000189. doi:10.1136/jitc-2019-000189.
[cited by applicant]
Czarnowicki et al., “Circulating CLA+ T cells in atopic dermatitis and their possible role as peripheral biomarkers,” Allergy 72 (2017) 366-372; DOI:10.1111/all.13080.
[cited by applicant]
Deng et al., “Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data,” mAbs, 3:1, 61-66 (2011); DOI: 10.4161/mabs.3.1.13799.
[cited by applicant]
Dirks et al., “Population Pharmacokinetics of Therapeutic Monoclonal Antibodies,” Clin. Pharmacokinet. 2010; 49 (10):633-659.
[cited by applicant]
“ICH guideline S6 (R1)—Preclinical safety evaluation of biotechnology-derived pharmaceuticals” Jun. 2011 EMA/CHMP/ICH/731268/1998, Committee for medicinal products for human use (CHMP).
[cited by applicant]
US Food and Drug Administration, “Guidance for Industry—Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers,” Jul. 2005, Pharmacology and Toxicology.
[cited by applicant]
US Food and Drug Administration, “International Conference on Harmonisation; Addendum to International Conference on Harmonisation Guidance on S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals; A…
[cited by applicant]
US Food and Drug Administration, “Nonclinical Safety Evaluation of the Immunotoxic Potential of Drugs and Biologics,” Feb. 2020.
[cited by applicant]
Foster-Cuevas et al., “Human Herpesvirus 8 K14 Protein Mimics CD200 in Down-Regulating Macrophage Activation through CD200 Receptor,” Journal of Virology, Jul. 2004, vol. 78, No. 14, p. 7667-7676; DOI: 10.1128/JVI.78.14…
[cited by applicant]
Ginos et al., “Identification of a Gene Expression Signature Associated with Recurrent Disease in Squamous Cell Carcinoma of the Head and Neck,” Cancer Research 64, 55-63, Jan. 1, 2004.
[cited by applicant]
Gorczinsky et al., “Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice,” Breast Cancer Res Treat (2010) 123:405-415; DOI 10.1007/s10549-009-0667-8.
[cited by applicant]
Gordon et al., “Identification of Novel Candidate Oncogenes and Tumor Suppressors in Malignant Pleural Mesothelioma Using Large-Scale Transcriptional Profiling,” American Journal of Pathology, vol. 166, No. 6, Jun. 2005.
[cited by applicant]
Hagemann et al., “Re-educating' tumor-associated macrophages by targeting NF-KB,” J. Exp. Med. vol. 205 No. 6 1261-1268; www.jem.org/cgi/doi/10.1084/jem.20080108.
[cited by applicant]
Hatherley et al., “The CD200 and CD200 receptor cell surface proteins interact through their N-terminal immunoglobulin-like domains,” Eur. J. Immunol. 2004. 34: 1688-1694.
[cited by applicant]
Hatherley et al., “Structures of CD200/CD200 Receptor Family and Implications for Topology, Regulation, and Evolution,” Structure 21, 820-832, May 7, 2013.
[cited by applicant]
Hayakawa et al., “CD200 increases alternatively activated macrophages through cAMP-response element binding protein—C/EBP-beta signaling,” Journal of Neurochemistry, 136: 900-906 (2016).
[cited by applicant]
Jacobsen et al., “Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability,” The Journal of Biological Chemistry vol. 292, No. 5, pp. 1865-1875, Feb. 3, 2017.
[cited by applicant]
Jenkins et al., “Mechanisms of resistance to immune checkpoint inhibitors,” British Journal of Cancer (2018) 118, 9-16; doi: 10.1038/bjc.2017.434.
[cited by applicant]
Klein et al., “Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells,” J. Exp. Med., vol. 194, No. 11, Dec. 3, 2001 1625-1638; www.jem.org/cgi/content…
[cited by applicant]
Koning et al., “Expression of the Inhibitory CD200 Receptor is Associated with Alternative Macrophage Activation,” J Innate Immun 2010;2:195-200; DOI: 10.1159/000252803.
[cited by applicant]
Korkola et al., “Down-Regulation of Stem Cell Genes, Including Those in a 200-kb Gene Cluster at 12p13.31, is Associated with In vivo Differentiation of Human Male Germ Cell Tumors,” Cancer Res 2006; 66: (2). Jan. 15, 2…
[cited by applicant]
Kretz-Rommel et al., “CD200 Expression on Tumor Cells Suppresses Antitumor Immunity: New Approaches to Cancer Immunotherapy,” J Immunol 2007; 178:5595-5605; doi: 10.4049/jimmunol.178.9.5595.
[cited by applicant]
Kyi et al., “Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges,” Immunotherapy (2016) 8(7), 821-837.
[cited by applicant]
Lau et al., “Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice,” Nature Communications, 8:14572; Published Feb. 21, 2017; DOI: 10.1038/ncomms14572.
[cited by applicant]
Lauzon et al., “Lung CD200 Receptor Activation Abrogates Airway Hyperresponsiveness in Experimental Asthma,” American Journal of Respiratory Cell and Molecular Biology vol. 53 No. 2 | Aug. 2015.
[cited by applicant]
Leabman et al., “Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys,” mAbs, 5:6, 896-903, DOI: 10.4161/mabs.26436.
[cited by applicant]
Lenburg et al., “Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data,” BMC Cancer 2003, 3:31. Published: Nov. 27, 2003.
[cited by applicant]
Li et al., “C-Rel is a myeloid checkpoint for cancer immunotherapy,” Nature Cancer, vol. 1, 507-517; May 2020.
[cited by applicant]
Love et al., “CD200 Expression in Neuroendocrine Neoplasms,” Am J Clin Pathol 2017;148:236-242. DOI: 10.1093/AJCP/AQX071.
[cited by applicant]
Mahadevan et al., “Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200,” Journal for ImmunoTherapy of Cancer (2019) 7:227; doi.org/10.1186/s40425-01…
[cited by applicant]
Markowitz et al., “Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival,” JCI Insight. 2018; 3(13):e96836. https://doi.org/10.1172/jci.insight.96836.
[cited by applicant]
McWhirter et al., “Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation,” PNAS, vol. 103, No. 4, 1041-1046. Jan. 24, 2006.
[cited by applicant]
Mihrshahi et al., “Essential Roles for Dok2 and RasGAP in CD200 Receptor-Mediated Regulation of Human Myeloid Cells,” J Immunol 2009; 183:4879-4886; Prepublished online Sep. 28, 2009.
[cited by applicant]
Mihrshahi et al., “Downstream of Tyrosine Kinase 1 and 2 Play Opposing Roles in CD200 Receptor Signaling,” J Immunol 2010; 185:7216-7222; Prepublished online Nov. 15, 2010; doi: 10.4049/jimmunol.1002858.
[cited by applicant]
Misstear et al., “Suppression of Antigen-Specific T Cell Responses by the Kaposi's Sarcoma-Associated Herpesvirus Viral OX2 Protein and Its Cellular Orthologue, CD200,” Journal of Virology, vol. 86, No. 11, p. 6246-6257…
[cited by applicant]